July 2026

New Products

• Abaloparatide (Eladynos) is an agonist of the parathyroid hormone receptor 1 (PTHR1). It shares sequence homology with the first 34 amino acids of parathyroid hormone related peptide [PTHrP(1-34)] (76% homology) and of parathyroid hormone [PTH(1-34)] (41% homology). Abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity.  Abaloparatide causes transient and limited increases in bone resorption and increases bone density. Eladynos is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Eladynos is contraindicated in women who are pregnant or breastfeeding; are of childbearing potential; have pre-existing hypercalcaemia; have severe renal impairment; have unexplained elevations of serum alkaline phosphatase; have known risks for osteosarcoma such as those who have received prior external beam or implant radiation therapy involving the skeleton; have skeletal malignancies or bone metastases. Eladynos solution for injection contains abaloparatide 2 mg per 1 mL and is available in packs of one 1.5 mL prefilled pen that delivers 30 doses of 80 mcg.
   
• Futibatinib (Lytgobi) is a tyrosine kinase inhibitor that irreversibly inhibits fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4 by covalent binding. FGFR signalling can support the proliferation and survival of malignant cells. Lytgobi monotherapy has provisional approval for the treatment of adult patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Lytgobi tablets contain futibatinib 4 mg and are available in packs of 35.
  
  Insulin degludec (Tresiba) is an ultra-long acting basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose lowering effect. Tresiba binds to the human insulin receptor resulting in the same pharmacological effects as human insulin. The blood glucose lowering effect of Tresiba is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.  Tresiba is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year. Tresiba penfill solution for injection contains insulin degludec 100 units per 1 mL and is available in packs of five 3 mL cartridges.
   
• Pneumococcal 21 valent polysaccharide conjugate vaccine (Capvaxive) is a conjugated polysaccharide that protects against invasive disease and pneumonia caused by Streptococcus pneumoniae. Capvaxive contains serotype‑specific pneumococcal purified capsular polysaccharides, which are known to contribute to the pathogenicity of pneumococci in adults. Each serotype of activated polysaccharide is individually conjugated to a carrier protein (diphtheria CRM₁₉₇ protein), and elicits antibodies that enhance opsonization, phagocytosis, and killing of pneumococci to protect against pneumococcal disease. Capvaxive elicits a T-cell dependent immune response. Carrier protein-specific helper T-cells support specificity, functionality, and maturation of serotype-specific B-cells. Pneumococcal conjugate vaccines have decreased the frequency of disease in populations vaccinated (direct impact), and in populations not vaccinated through reduction of colonisation and transmission (indirect impact). As with any vaccine, Capvaxive may not protect all vaccine recipients. Capvaxive is indicated for active immunisation for the prevention of pneumococcal disease caused by S. pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older. Capvaxive is contraindicated in individuals with a history of a severe allergic reaction (e.g. anaphylaxis) to the active substances and diphtheria toxoid. Capvaxive solution for injection contains 84 mcg of pneumococcal purified capsular polysaccharide antigen (4 mcg each of serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, 35B) conjugated to approximately 65 mcg of diphtheria CRM₁₉₇ protein. It is available in 0.5 mL prefilled syringes in packs of 1 or 10.
   
• Tezepelumab (Tezspire) is a human immunoglobulin G2 lamda (IgG2 lamda) monoclonal antibody directed against thymic stromal lymphopoietin (TSLP) that binds to human TSLP with high affinity and prevents its interaction with the heterodimeric TSLP receptor. TSLP, an epithelial cell-derived cytokine, occupies an upstream position in the asthma inflammatory cascade and plays a role in the initiation and persistence of airway inflammation in asthma. TSLP regulates immunity at the airway barrier surface, affecting dendritic cells and other innate and adaptive immune cells, and inducing downstream inflammatory processes and bronchial hyper-responsiveness. TSLP has also been shown to have indirect effects on airway structural cells (e.g. fibroblasts and airway smooth muscle). In asthma, both allergic and non-allergic triggers induce TSLP production. Blocking TSLP with tezepelumab reduces a broad spectrum of biomarkers and cytokines associated with inflammation (e.g. blood eosinophils, IgE, FeNO, interleukin (IL)-5, and IL-13). Tezspire is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma who are inadequately controlled despite optimal therapy including medium or high dose inhaled corticosteroids plus another non-steroidal medicinal product for maintenance treatment. Tezspire solution for injection contains tezepelumab 210 mg per 1.9 mL and is available in packs of 1 prefilled pen.

New Presentation

• Selpercatinib (Retevmo Tablets) is now available as tablets containing selpercatinib 40 mg or 80 mg in packs of 56.

New Indications

• Daratumumab (rch) (Darzalex SC) is now also indicated in combination with lenalidomide and dexamethasone; or bortezomib, lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. 
   
• Melatonin (Slenyto) is now indicated for the treatment of insomnia in children and adolescents aged 2-18 years with neurogenetic disorders with aberrant diurnal melatonin secretion and/or nocturnal awakenings, where sleep hygiene measures have been insufficient.
   
• Sotatercept (Winrevair) in combination with standard therapy is now indicated for the treatment of adults with pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Functional Class (FC) IV.

New Contraindications

• Suxamethonium chloride dihydrate (Suxamethonium Medsurge) is now also contraindicated in patients with inherited atypical or low serum level of pseudocholinesterase, end stage hepatic failure, acute or chronic renal failure; in patients recovering from major trauma or severe burns (the period of greatest risk of hyperkalaemia is from about 5 to 90 days after the injury and may be further prolonged if there is delayed healing due to persistent infection); a patient who is not fully anaesthetised; in patients with neurological deficits involving acute major muscle wasting (upper and/or lower motor neurone lesions); in patients who have been immobilised for prolonged periods of time; in patients with cerebral palsy; and in patients with a personal or family history of congenital myotonic diseases such as myotonia congenita and dystrophia myotonica. 
   
• Tranexamic acid (Tranexamic-AFT) is now also contraindicated for intrathecal or epidural administration.

Safety Related Changes

• Entrectinib (Rozlytrek) no longer has provisional approval and is now not indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy.
   
• Terlipressin (acetate) (Glypressin Solution) is no longer contraindicated in patients with current or recent ischaemic cardiovascular disease.

This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.